Research on GLP-1 drugs and binge eating disorder asks whether the frequency of binge episodes changes. Food-noise research focuses on persistent thoughts about food and how disruptive those thoughts feel. One research questionnaire uses five items to measure that experience [1].
The study of eating behavior in a Brazilian clinic used another questionnaire to track several eating behaviors. Its results answer a broader question than how often participants think about food.
What did people using semaglutide report?
The U.S. INFORM survey enrolled 550 adults already using injectable semaglutide for weight management. Among the 547 with complete questionnaire answers, the median score was 6 out of 20 at the time of the survey. Their median recalled score before treatment was 13 out of 20. Novo Nordisk funded the survey. It did not collect scores before treatment, and it recruited current users rather than following everyone who started [2].
A separate study included 79 adults with obesity: 27 who had not started GLP-1 treatment, 25 one-month users and 27 six-month users. The six-month users had lower Food Noise Questionnaire scores than people who had not started. The researchers compared different people at one point in time [3].
What did a placebo-controlled trial measure?
In a 60-week randomized trial, people assigned to semaglutide reported less food preoccupation over the previous week at week 20 than people assigned placebo. There was no statistically clear difference in the appetite measures at weeks 40 or 60. This study used an item from the Control of Eating Questionnaire, a different measure from the five-item food-noise questionnaire [4].
What do newer telehealth studies add?
In November 2026 conference reports, Novo Nordisk and Ro described lower scores after patients started injectable or oral semaglutide. These analyses used a different food-noise questionnaire and included people with a baseline and follow-up who stayed on treatment under the studies’ definitions. Both analyses used telehealth records without a randomized comparison group, so the reported change may differ for people who stop treatment early or follow a different care program [5].